Association Between Human Papillomavirus Vaccination and Primary Ovarian Insufficiency in a Nationwide Cohort

Anders Hviid, Emilia Myrup Thiesson, Anders Hviid, Emilia Myrup Thiesson

Abstract

Importance: Anecdotal case reports have suggested an association between human papillomavirus (HPV) vaccination and primary ovarian insufficiency, but observational studies of HPV and primary ovarian insufficiency are rare, and their findings do not support an association. However, available studies have been limited by statistical power, and concerns about infertility after vaccination are associated with lower levels of uptake of the cancer-preventing vaccine in many countries.

Objective: To evaluate the risk of primary ovarian insufficiency after quadrivalent human papillomavirus (4HPV) vaccination.

Design, setting, and participants: This retrospective cohort study with follow-up from 2007 to 2016 used nationwide data for 996 300 Danish-born girls and women aged 11 to 34 years. Cox proportional hazards regression was used to estimate hazard ratios (HRs) of primary ovarian insufficiency diagnoses by 4HPV vaccination status with adjustment for age, calendar period, and a propensity score summarizing health care use. Data were analyzed from October 2020 to January 2021.

Exposures: Receiving 4HPV vaccination compared with receiving no vaccination.

Main outcomes and measures: The main outcome was hospital contacts for primary ovarian insufficiency, and the main outcome measures were HRs comparing rates of primary ovarian insufficiency among vaccinated and unvaccinated individuals.

Results: During 6 781 166 person-years of follow-up among 996 300 girls and women aged 11 to 34 years (505 829 vaccinated individuals [50.8%] and 490 471 unvaccinated individuals [49.2%]), 144 individuals were diagnosed with primary ovarian insufficiency, including 54 individuals diagnosed after 4HPV vaccination. The median (interquartile range) age of primary ovarian insufficiency diagnosis was 26.94 (12.68) years. The adjusted HR of primary ovarian insufficiency comparing 4HPV vaccination to no vaccination was 0.96 (95% CI, 0.55-1.68).

Conclusions and relevance: This study found no association between HPV vaccination and primary ovarian insufficiency. However, given the rarity of the outcome in this study, the presence of a clinically relevant increase in rate of diagnosis cannot be excluded.

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure 1.. Study Flowchart
Figure 1.. Study Flowchart
Figure 2.. Cumulative Incidence of Primary Ovarian…
Figure 2.. Cumulative Incidence of Primary Ovarian Insufficiency by Vaccination Status
Shaded areas indicate 95% confidence bands.

References

    1. Barboi A, Gibbons CH, Axelrod F, et al. ; American Autonomic Society . Human papillomavirus (HPV) vaccine and autonomic disorders: a position statement from the American Autonomic Society. Clin Auton Res. 2020;30(1):13-18. doi:10.1007/s10286-019-00608-w
    1. Karafillakis E, Simas C, Jarrett C, et al. . HPV vaccination in a context of public mistrust and uncertainty: a systematic literature review of determinants of HPV vaccine hesitancy in Europe. Hum Vaccin Immunother. 2019;15(7-8):1615-1627. doi:10.1080/21645515.2018.1564436
    1. Little DT, Ward HRG. Adolescent premature ovarian insufficiency following human papillomavirus vaccination: a case series seen in general practice. J Investig Med High Impact Case Rep. 2014;2(4):2324709614556129. doi:10.1177/2324709614556129
    1. Colafrancesco S, Perricone C, Tomljenovic L, Shoenfeld Y. Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants. Am J Reprod Immunol. 2013;70(4):309-316. doi:10.1111/aji.12151
    1. Gruber N, Shoenfeld Y. A link between human papilloma virus vaccination and primary ovarian insufficiency: current analysis. Curr Opin Obstet Gynecol. 2015;27(4):265-270. doi:10.1097/GCO.0000000000000183
    1. Little DT, Ward HR. Ongoing inadequacy of quadrivalent HPV vaccine safety studies. BMJ Evid Based Med. 2020;25(2):44-45. doi:10.1136/bmjebm-2018-111122
    1. Naleway AL, Mittendorf KF, Irving SA, et al. . Primary ovarian insufficiency and adolescent vaccination. Pediatrics. 2018;142(3):e20180943. doi:10.1542/peds.2018-0943
    1. Arana JE, Harrington T, Cano M, et al. . Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015. Vaccine. 2018;36(13):1781-1788. doi:10.1016/j.vaccine.2018.02.034
    1. Pedersen CB. The Danish Civil Registration System. Scand J Public Health. 2011;39(7)(suppl):22-25. doi:10.1177/1403494810387965
    1. Grove Krause T, Jakobsen S, Haarh M, Mølbak K. The Danish vaccination register. Euro Surveill. 2012;17(17):20155. doi:10.2807/ese.17.17.20155-en
    1. Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449-490. doi:10.2147/CLEP.S91125
    1. D’Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19):2265-2281. doi:10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>;2-B
    1. Westreich D, Cole SR, Funk MJ, Brookhart MA, Stürmer T. The role of the C-statistic in variable selection for propensity score models. Pharmacoepidemiol Drug Saf. 2011;20(3):317-320. doi:10.1002/pds.2074
    1. Christianson MS, Wodi P, Talaat K, Halsey N. Primary ovarian insufficiency and human papilloma virus vaccines: a review of the current evidence. Am J Obstet Gynecol. 2020;222(3):239-244. doi:10.1016/j.ajog.2019.08.045
    1. Little DT, Ward HRG. Premature ovarian failure 3 years after menarche in a 16-year-old girl following human papillomavirus vaccination. BMJ Case Rep. 2012;2012:bcr2012006879. doi:10.1136/bcr-2012-006879
    1. Hawkes D. Evidence evolves over time and should be based on data not opinion. BMJ Evid Based Med. 2020;25(6):191-192. doi:10.1136/bmjebm-2019-111222
    1. Hawkes D, Buttery JP. Human papillomavirus vaccination and primary ovarian insufficiency: an association based on ideology rather than evidence. Curr Opin Obstet Gynecol. 2016;28(1):70-72. doi:10.1097/GCO.0000000000000240
    1. Pellegrino P, Carnovale C, Perrone V, et al. . On the association between human papillomavirus vaccine and primary ovarian failure. Am J Reprod Immunol. 2014;71(4):293-294. doi:10.1111/aji.12190
    1. Gong L, Ji HH, Tang XW, Pan LY, Chen X, Jia YT. Human papillomavirus vaccine-associated premature ovarian insufficiency and related adverse events: data mining of Vaccine Adverse Event Reporting System. Sci Rep. 2020;10(1):10762. doi:10.1038/s41598-020-67668-1
    1. Schmuhl NB, Mooney KE, Zhang X, Cooney LG, Conway JH, LoConte NK. No association between HPV vaccination and infertility in U.S. females 18-33 years old. Vaccine. 2020;38(24):4038-4043. doi:10.1016/j.vaccine.2020.03.035
    1. Lei J, Ploner A, Elfström KM, et al. . HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020;383(14):1340-1348. doi:10.1056/NEJMoa1917338
    1. Yuan S, Qiu Y, Xu Y, Wang H. Human papillomavirus infection and female infertility: a systematic review and meta-analysis. Reprod Biomed Online. 2020;40(2):229-237. doi:10.1016/j.rbmo.2019.10.019

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren